Improvement of early miscarriage rates in women with adenomyosis via oxytocin receptor antagonist during frozen embryo transfer-a propensity score-matched study.
Humans
Female
Embryo Transfer
/ methods
Adult
Pregnancy
Propensity Score
Adenomyosis
/ complications
Fertilization in Vitro
/ methods
Abortion, Spontaneous
/ epidemiology
Receptors, Oxytocin
/ antagonists & inhibitors
Pregnancy Rate
Infertility, Female
/ therapy
Retrospective Studies
Cryopreservation
Hormone Replacement Therapy
/ methods
Hormone Antagonists
/ therapeutic use
Adenomyosis
Atosiban
Frozen embryo transfer
In vitro fertilization
Oxytocin receptor antagonist
Journal
Reproductive biology and endocrinology : RB&E
ISSN: 1477-7827
Titre abrégé: Reprod Biol Endocrinol
Pays: England
ID NLM: 101153627
Informations de publication
Date de publication:
12 Jul 2024
12 Jul 2024
Historique:
received:
11
05
2024
accepted:
03
07
2024
medline:
13
7
2024
pubmed:
13
7
2024
entrez:
12
7
2024
Statut:
epublish
Résumé
Dysfunctional uterine peristalsis seems to play a pivotal role in hindering embryo implantation among women diagnosed with adenomyosis. This research aims to investigate whether administering an oxytocin receptor antagonist during a frozen embryo transfer (FET) cycle using a hormone replacement therapy (HRT) protocol can enhance in vitro fertilization (IVF) outcomes for infertile women affected by adenomyosis. Between January 2018 and June 2022, our reproductive center conducted IVF-FET HRT cycles for infertile women diagnosed with adenomyosis. Propensity score matching was employed to select matched subjects between the two groups in a 1:1 ratio. Following this, 168 women received an oxytocin receptor antagonist during FET, constituting the study group, while the matched 168 women underwent FET without this antagonist, forming the control group. We conducted comparative analyses of baseline and cycle characteristics between the two groups, along with additional subgroup analyses. The study group exhibited notably lower rates of early miscarriage compared to the control group, although there were no significant differences in clinical pregnancy rates, ongoing pregnancy rates, and live birth rates between the two groups. Multivariate analysis revealed a negative correlation between the use of oxytocin receptor antagonists and early miscarriage rates in women with adenomyosis. Subgroup analyses, categorized by age, infertility types, and embryo transfer day, showed a substantial decrease in early miscarriage rates within specific subgroups: women aged ≥ 37 years, those with secondary infertility, and individuals undergoing day 3 embryo transfers in the study group compared to the control group. Furthermore, subgroup analysis based on adenomyosis types indicated significantly higher clinical pregnancy rates, ongoing pregnancy rates and live birth rates in the study group compared to the control group among women with diffuse adenomyosis. Administering an oxytocin receptor antagonist during FET may reduce the early miscarriage rates in women with adenomyosis.
Sections du résumé
BACKGROUND
BACKGROUND
Dysfunctional uterine peristalsis seems to play a pivotal role in hindering embryo implantation among women diagnosed with adenomyosis. This research aims to investigate whether administering an oxytocin receptor antagonist during a frozen embryo transfer (FET) cycle using a hormone replacement therapy (HRT) protocol can enhance in vitro fertilization (IVF) outcomes for infertile women affected by adenomyosis.
METHODS
METHODS
Between January 2018 and June 2022, our reproductive center conducted IVF-FET HRT cycles for infertile women diagnosed with adenomyosis. Propensity score matching was employed to select matched subjects between the two groups in a 1:1 ratio. Following this, 168 women received an oxytocin receptor antagonist during FET, constituting the study group, while the matched 168 women underwent FET without this antagonist, forming the control group. We conducted comparative analyses of baseline and cycle characteristics between the two groups, along with additional subgroup analyses.
RESULTS
RESULTS
The study group exhibited notably lower rates of early miscarriage compared to the control group, although there were no significant differences in clinical pregnancy rates, ongoing pregnancy rates, and live birth rates between the two groups. Multivariate analysis revealed a negative correlation between the use of oxytocin receptor antagonists and early miscarriage rates in women with adenomyosis. Subgroup analyses, categorized by age, infertility types, and embryo transfer day, showed a substantial decrease in early miscarriage rates within specific subgroups: women aged ≥ 37 years, those with secondary infertility, and individuals undergoing day 3 embryo transfers in the study group compared to the control group. Furthermore, subgroup analysis based on adenomyosis types indicated significantly higher clinical pregnancy rates, ongoing pregnancy rates and live birth rates in the study group compared to the control group among women with diffuse adenomyosis.
CONCLUSIONS
CONCLUSIONS
Administering an oxytocin receptor antagonist during FET may reduce the early miscarriage rates in women with adenomyosis.
Identifiants
pubmed: 38997744
doi: 10.1186/s12958-024-01255-1
pii: 10.1186/s12958-024-01255-1
doi:
Substances chimiques
Receptors, Oxytocin
0
Hormone Antagonists
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
79Informations de copyright
© 2024. The Author(s).
Références
Kuijsters NPM, Methorst WG, Kortenhorst MSQ, Rabotti C, Mischi M, Schoot BC. Uterine peristalsis and fertility: current knowledge and future perspectives: a review and meta-analysis. Reprod Biomed Online. 2017;35(1):50–71.
doi: 10.1016/j.rbmo.2017.03.019
pubmed: 28456372
Rees CO, de Boer A, Huang Y, Wessels B, Blank C, Kuijsters N, Huppelschoten A, Zizolfi B, Foreste V, Di Spiezio Sardo A, et al. Uterine contractile activity in healthy women throughout the menstrual cycle measured using a novel quantitative two-dimensional transvaginal ultrasound speckle tracking method. Reprod Biomed Online. 2023;46(1):115–22.
doi: 10.1016/j.rbmo.2022.08.104
pubmed: 36244894
Fanchin R, Righini C, Olivennes F, Taylor S, de Ziegler D, Frydman R. Uterine contractions at the time of embryo transfer alter pregnancy rates after in-vitro fertilization. Hum Reprod. 1998;13(7):1968–74.
doi: 10.1093/humrep/13.7.1968
pubmed: 9740459
Zhu L, Che HS, Xiao L, Li YP. Uterine peristalsis before embryo transfer affects the chance of clinical pregnancy in fresh and frozen-thawed embryo transfer cycles. Hum Reprod. 2014;29(6):1238–43.
doi: 10.1093/humrep/deu058
pubmed: 24664129
Javedani Masroor M, Younesi Asl L, Sarchami N. The effect of uterine contractions on fertility outcomes in frozen embryo transfer cycles: a Cohort Study. J Reprod Infertil. 2023;24(2):132–8.
pubmed: 37547572
pmcid: 10402453
Chung CH, Wong AW, Chan CP, Saravelos SH, Kong GW, Cheung LP, Chung JP, Li TC. The changing pattern of uterine contractions before and after fresh embryo transfer and its relation to clinical outcome. Reprod Biomed Online. 2017;34(3):240–7.
doi: 10.1016/j.rbmo.2016.12.011
pubmed: 28089077
Shmygol A, Gullam J, Blanks A, Thornton S. Multiple mechanisms involved in oxytocin-induced modulation of myometrial contractility. Acta Pharmacol Sin. 2006;27(7):827–32.
doi: 10.1111/j.1745-7254.2006.00393.x
pubmed: 16787565
Arrowsmith S, Wray S. Oxytocin: its mechanism of action and receptor signalling in the myometrium. J Neuroendocrinol. 2014;26(6):356–69.
doi: 10.1111/jne.12154
pubmed: 24888645
Shubert PJ. Atosiban. Clin Obstet Gynecol. 1995;38(4):722–4.
doi: 10.1097/00003081-199538040-00007
pubmed: 8616970
Melin P. Oxytocin antagonists in preterm labour and delivery. Baillieres Clin Obstet Gynaecol. 1993;7(3):577–600.
doi: 10.1016/S0950-3552(05)80449-3
pubmed: 8252818
Vrachnis N, Malamas FM, Sifakis S, Deligeoroglou E, Iliodromiti Z. The oxytocin-oxytocin receptor system and its antagonists as tocolytic agents. Int J Endocrinol. 2011;2011:350546.
doi: 10.1155/2011/350546
pubmed: 22190926
pmcid: 3235456
Chandraharan E, Arulkumaran S. Acute tocolysis. Curr Opin Obstet Gynecol. 2005;17(2):151–6.
doi: 10.1097/01.gco.0000162184.45854.88
pubmed: 15758607
Neumann K, Griesinger G. Is oxytocin receptor antagonist administration around embryo transfer associated with IVF treatment success? A systematic review and meta-analysis. Reprod Biomed Online. 2021;43(6):983–94.
doi: 10.1016/j.rbmo.2021.08.020
pubmed: 34686417
Li J, Chen Y, Wang A, Zhang H. A meta-analysis of atosiban supplementation among patients undergoing assisted reproduction. Arch Gynecol Obstet. 2017;296(4):623–34.
doi: 10.1007/s00404-017-4455-0
pubmed: 28695395
Tyler B, Walford H, Tamblyn J, Keay SD, Mavrelos D, Yasmin E, Al Wattar BH. Interventions to optimize embryo transfer in women undergoing assisted conception: a comprehensive systematic review and meta-analyses. Hum Reprod Update 2022.
Yuan C, Song H, Fan L, Su S, Dong B. The Effect of Atosiban on patients with difficult embryo transfers undergoing in Vitro fertilization-embryo transfer. Reprod Sci. 2019;26(12):1613–7.
doi: 10.1177/1933719119831791
pubmed: 30791824
Wang R, Huang H, Tan Y, Xia G. Efficacy of atosiban for repeated embryo implantation failure: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1161707.
doi: 10.3389/fendo.2023.1161707
pubmed: 37033236
Craciunas L, Tsampras N, Kollmann M, Raine-Fenning N, Choudhary M. Oxytocin antagonists for assisted reproduction. Cochrane Database Syst Rev. 2021;9:CD012375.
pubmed: 34467530
Ge C, Zhang B, Mao Y, Hong Z, Zhou C, Wang Y, Wang M, Ma L. Effects of atosiban on clinical outcome in frozen-thawed embryo transfer: a propensity score matching study. Arch Gynecol Obstet. 2024;309(3):1101–6.
doi: 10.1007/s00404-023-07289-x
pubmed: 38240770
Li X, Du Y, Han X, Wang H, Sheng Y, Lian F, Lian Q. Efficacy of atosiban for repeated implantation failure in frozen embryo transfer cycles. Sci Rep. 2023;13(1):9277.
doi: 10.1038/s41598-023-36286-y
pubmed: 37286752
pmcid: 10247710
Li J, Mo S, Lin Z, Shi Q. Atosiban application in fresh ET cycle is effective for women undergoing repeated embryo implantation failures, especially for advanced-age obese patients. Sci Rep. 2023;13(1):23044.
doi: 10.1038/s41598-023-49773-z
pubmed: 38155160
pmcid: 10754826
Tang CL, Li QY, Chen FL, Cai CT, Dong YY, Wu YY, Yang JZ, Zhao M, Chi FL, Hong L, et al. A randomized double blind comparison of atosiban in patients with recurrent implantation failure undergoing IVF treatment. Reprod Biol Endocrinol. 2022;20(1):124.
doi: 10.1186/s12958-022-00999-y
pubmed: 35986323
pmcid: 9389813
Buddhabunyakan N, Sothornwit J, Seejorn K, Buppasiri P, Salang L. Effects of atosiban on uterine peristalsis following frozen embryo transfer: a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2021;265:96–101.
doi: 10.1016/j.ejogrb.2021.08.017
pubmed: 34478926
Ng EH, Li RH, Chen L, Lan VT, Tuong HM, Quan S. A randomized double blind comparison of atosiban in patients undergoing IVF treatment. Hum Reprod. 2014;29(12):2687–94.
doi: 10.1093/humrep/deu263
pubmed: 25336707
Rees CO, Thomas S, de Boer A, Huang Y, Zizolfi B, Foreste V, di Spiezio di Sardo A, Christoforidis N, van Vliet H, Mischi M, et al. Quantitative ultrasound measurement of uterine contractility in adenomyotic vs. normal uteri: a multicenter prospective study. Fertil Steril. 2024;121(5):864–72.
doi: 10.1016/j.fertnstert.2024.01.009
pubmed: 38199285
Arena A, Zanello M, Orsini B, Degli Esposti E, Iodice R, Altieri M, Borgia A, Moro E, Seracchioli R, Casadio P. Uterine peristalsis in women affected by adenomyosis: a step towards functional assessment. Int J Gynaecol Obstet. 2024;165(2):666–71.
doi: 10.1002/ijgo.15299
pubmed: 38205860
Cozzolino M, Tartaglia S, Pellegrini L, Troiano G, Rizzo G, Petraglia F. The effect of uterine adenomyosis on IVF outcomes: a systematic review and Meta-analysis. Reprod Sci. 2022;29(11):3177–93.
doi: 10.1007/s43032-021-00818-6
pubmed: 34981458
Younes G, Tulandi T. Effects of adenomyosis on in vitro fertilization treatment outcomes: a meta-analysis. Fertil Steril. 2017;108(3):483–e490483.
doi: 10.1016/j.fertnstert.2017.06.025
pubmed: 28865548
Moawad G, Kheil MH, Ayoubi JM, Klebanoff JS, Rahman S, Sharara FI. Adenomyosis and infertility. J Assist Reprod Genet. 2022;39(5):1027–31.
doi: 10.1007/s10815-022-02476-2
pubmed: 35347501
pmcid: 9107544
Qu M, Lu P, Bellve K, Lifshitz LM, ZhuGe R. Mode switch of ca(2 +) oscillation-mediated uterine peristalsis and Associated embryo implantation impairments in mouse adenomyosis. Front Physiol. 2021;12:744745.
doi: 10.3389/fphys.2021.744745
pubmed: 34803733
pmcid: 8599363
Pados G, Gordts S, Sorrentino F, Nisolle M, Nappi L, Daniilidis A. Adenomyosis and infertility: a Literature Review. Med (Kaunas) 2023, 59(9).
Van den Bosch T, de Bruijn AM, de Leeuw RA, Dueholm M, Exacoustos C, Valentin L, Bourne T, Timmerman D, Huirne JAF. Sonographic classification and reporting system for diagnosing adenomyosis. Ultrasound Obstet Gynecology: Official J Int Soc Ultrasound Obstet Gynecol. 2019;53(5):576–82.
doi: 10.1002/uog.19096
Han B, Liang T, Zhang W, Ma C, Qiao J. The effect of adenomyosis types on clinical outcomes of IVF embryo transfer after ultra-long GnRH agonist protocol. Reprod Biomed Online. 2023;46(2):346–51.
doi: 10.1016/j.rbmo.2022.09.021
pubmed: 36549997
Exacoustos C, Morosetti G, Conway F, Camilli S, Martire FG, Lazzeri L, Piccione E, Zupi E. New Sonographic classification of adenomyosis: do type and degree of adenomyosis correlate to severity of symptoms? J Minim Invasive Gynecol. 2020;27(6):1308–15.
doi: 10.1016/j.jmig.2019.09.788
pubmed: 31600574
The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. Hum Reprod. 2011, 26(6):1270–1283.
Wang Y, Yi YC, Guu HF, Chen YF, Kung HF, Chang JC, Chen LY, Chuan ST, Chen MJ. Impact of adenomyosis and endometriosis on IVF/ICSI pregnancy outcome in patients undergoing gonadotropin-releasing hormone agonist treatment and frozen embryo transfer. Sci Rep. 2023;13(1):6741.
doi: 10.1038/s41598-023-34045-7
pubmed: 37185812
pmcid: 10130073
Sachs-Guedj N, Coroleu B, Pascual M, Rodríguez I, Polyzos NP. Presence of Adenomyosis impairs clinical outcomes in women undergoing frozen embryo transfer: a retrospective cohort study. J Clin Med 2023, 12(18).
Mavrelos D, Holland TK, O’Donovan O, Khalil M, Ploumpidis G, Jurkovic D, Khalaf Y. The impact of adenomyosis on the outcome of IVF-embryo transfer. Reprod Biomed Online. 2017;35(5):549–54.
doi: 10.1016/j.rbmo.2017.06.026
pubmed: 28802706
Stanekova V, Woodman RJ, Tremellen K. The rate of euploid miscarriage is increased in the setting of adenomyosis. Hum Reprod Open. 2018;2018(3):hoy011.
doi: 10.1093/hropen/hoy011
pubmed: 30895252
pmcid: 6276689
Mehasseb MK, Panchal R, Taylor AH, Brown L, Bell SC, Habiba M. Estrogen and progesterone receptor isoform distribution through the menstrual cycle in uteri with and without adenomyosis. Fertil Steril. 2011;95(7):2228–35. 2235.e2221.
doi: 10.1016/j.fertnstert.2011.02.051
pubmed: 21444077
Pirtea P, de Ziegler D, Ayoubi JM. Endometrial receptivity in adenomyosis and/or endometriosis. Fertil Steril. 2023;119(5):741–5.
doi: 10.1016/j.fertnstert.2023.03.004
pubmed: 36914148
Günther V, Allahqoli L, Gitas G, Maass N, Tesch K, Ackermann J, Rosam P, Mettler L, von Otte S, Alkatout I. Impact of adenomyosis on infertile patients-Therapy options and Reproductive outcomes. Biomedicines 2022, 10(12).
He Y, Wu H, He X, Xing Q, Zhou P, Cao Y, Wei Z. Administration of atosiban in patients with endometriosis undergoing frozen-thawed embryo transfer: a prospective, randomized study. Fertil Steril. 2016;106(2):416–22.
doi: 10.1016/j.fertnstert.2016.04.019
pubmed: 27143518
He Y, Wu H, He X, Xing Q, Zhou P, Cao Y, Wei Z. Application of atosiban in frozen-thawed cycle patients with different times of embryo transfers. Gynecol Endocrinol. 2016;32(10):811–5.
doi: 10.1080/09513590.2016.1180680
pubmed: 27147474